CNS Pharmaceuticals, Inc.
CNSPNASDAQHealthcareBiotechnology
Previous close
$5.83
−$0.17 · -2.83%
CNSP company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Sell
Trim exposure — unfavorable risk-reward
Valuation
43
Fair Value
Momentum
39
Weakening
Sentiment
53
Mixed
Risk resilience
31
High Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteCNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical firm primarily focused on developing innovative anti-cancer therapies for tumors affecting the brain and central nervous system. Its primary investigational compound, Berubicin, an anthracycline, is currently progressing through Phase I and II clinical trials as a potential treatment for glioblastoma multiforme, an aggressive form of brain cancer. To bolster its research and development initiatives, the company has entered into several strategic agreements. These include licensing arrangements with Houston Pharmaceuticals, Inc., The University of Texas M.D. Anderson Cancer Center, and Animal Life Sciences, LLC. Additionally, CNS Pharmaceuticals has a development agreement in place with WPD Pharmaceuticals Inc. and a collaborative partnership with Reata Pharmaceuticals, Inc. The company was founded in 2017 and is headquartered in Houston, Texas.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Rami Levin
- Listed since
- Nov 8, 2019
- Employees
- 8
Market position
Day range
Current $5.83
52-week range
Current $5.83
- Open
- $5.965
- Previous close
- $6.00
- Volume
- 7.87K
- 0.01× average
- Average volume
- 1.43M
- Average daily volume
- Market cap
- 8.52M USD
- Beta
- 0.98
- Market reference 1
- 50-day average
- $5.0735
- +14.91% above average
- 200-day average
- $4.8787
- +19.50% above average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- -4.54M USD
- P/E (TTM)
- -0.25×
- P/B (TTM)
- 2.19×
- P/S (TTM)
- 0×
- EV / EBITDA
- 0.29×
- Earnings yield
- -680.96%
- Free cash flow yield
- -594.12%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 0.00%
- Operating margin
- 0.00%
- Net margin
- 0.00%
- Return on equity
- -350.48%
- Return on assets
- -183.81%
- Return on invested capital
- -329.54%
Financial health
- Debt / equity
- 0×
- Current ratio
- 1.98×
- Altman Z-score
- -7.03
- Piotroski F-score
- 1 of 9
Financial statements
Income trends
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | — | 3.31K USD | 4.13K USD | 11.76K USD | 13.07K USD |
| Gross profit | — | −3.31K USD | −4.13K USD | −11.76K USD | −13.07K USD |
| Research and development | 9.77M USD | 9.29M USD | 14.1M USD | 9.3M USD | 9.81M USD |
| Selling, general, and administrative | 6.21M USD | 5.61M USD | 4.77M USD | 5.62M USD | 4.67M USD |
| Operating expenses | 15.99M USD | 14.9M USD | 18.86M USD | 14.92M USD | 14.47M USD |
| Interest income | 153.79K USD | 60.26K USD | 27.69K USD | 7.03 USD | 9.29 USD |
| Interest expense | 15.23K USD | 16.12K USD | 13.81K USD | 7.03K USD | 9.29K USD |
| Depreciation and amortization | 3.92K USD | 3.31K USD | 4.13K USD | 11.76K USD | 13.07K USD |
| Operating income | −15.99M USD | −14.9M USD | −18.87M USD | −14.93M USD | −14.49M USD |
| Net income | −15.85M USD | −14.86M USD | −18.85M USD | −15.27M USD | −14.5M USD |
Company facts updated Aug 24, 2026.
Earnings
- EPS beat rate
- 40%
- 4 beats, 5 misses, 1 met estimate
- Average EPS surprise
- -15035.89%
- 10 comparable reports
- Latest EPS result
- -0.38
- Estimate -0.24 · Miss by 58.33%
EPS: actual versus estimate
Recent quarterly results
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Analyst price target
Average target
$0.50
91.42% downsideRating distribution
4 ratingsLimited analyst sample: 4 ratings. Interpret the distribution with caution.
Recent analyst actions
CNSP news
Corporate actions
Corporate action history
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Jul 22, 2025 | 1:12 | — | — |
Stock split | Feb 21, 2025 | 1:50 | — | — |
Stock split | Jun 5, 2024 | 1:50 | — | — |
Stock split | Nov 29, 2022 | 1:30 | — | — |
Effective Jul 22, 2025
1:12
Effective Feb 21, 2025
1:50
Effective Jun 5, 2024
1:50
Effective Nov 29, 2022
1:30
CNSP peers
ETFs holding CNSP
Funds reporting this stock among their holdings, ordered by reported position size.
Continue in GoAI
Research CNSPresearch.disclaimer